TABLE 3. Reactions reported by adolescents aged 12–17 years (N = 129,059) who completed at least one v-safe health check-in survey on days 0–7 after receiving Pfizer BioNTech COVID-19 vaccine — United States, December 14, 2020–July 16, 2021.
| Event | % of v-safe enrollees reporting reaction or health impact* |
|||
|---|---|---|---|---|
| Age 16–17 yrs, dose (no.) |
Age 12–15 yrs, dose (no.) |
|||
| Dose 1 (66,350) | Dose 2 (41,040) | Dose 1 (62,709) | Dose 2 (38,817) | |
|
Any injection site reaction
|
62.7 |
64.4 |
63.9 |
62.4 |
| Itching |
5.7 |
6.3 |
5.8 |
5.5 |
| Pain |
60.2 |
62.0 |
61.2 |
59.9 |
| Redness |
3.4 |
4.9 |
4.1 |
5.3 |
| Swelling |
7.7 |
9.9 |
7.5 |
8.9 |
|
Any systemic reaction
|
55.7 |
69.9 |
48.9 |
63.4 |
| Abdominal pain |
4.7 |
8.5 |
4.1 |
7.0 |
| Myalgia |
25.4 |
40.7 |
21.4 |
31.4 |
| Chills |
8.3 |
26.2 |
6.8 |
21.1 |
| Diarrhea |
4.2 |
4.9 |
3.1 |
3.3 |
| Fatigue |
34.1 |
52.3 |
27.4 |
44.6 |
| Fever |
9.9 |
31.0 |
9.3 |
29.9 |
| Headache |
29.8 |
50.6 |
25.2 |
43.7 |
| Joint pain |
7.9 |
18.2 |
6.3 |
12.4 |
| Nausea |
10.2 |
19.8 |
7.5 |
14.8 |
| Rash |
1.2 |
1.1 |
1.2 |
1.2 |
| Vomiting |
1.1 |
2.3 |
1.0 |
2.6 |
|
Any health impact
|
11.0 |
28.6 |
10.6 |
25.4 |
| Unable to perform normal daily activities |
9.0 |
24.7 |
9.3 |
23.1 |
| Unable to work or attend school |
3.7 |
11.6 |
2.4 |
6.1 |
| Needed medical care |
0.5 |
0.6 |
0.5 |
0.8 |
| Telehealth |
0.1 |
0.2 |
0.1 |
0.2 |
| Clinic |
0.2 |
0.2 |
0.2 |
0.3 |
| Emergency department visit |
0.1 |
0.2 |
0.1 |
0.2 |
| Hospitalization | 0.02 | 0.03 | 0.02 | 0.04 |
* Percentage of enrollees who reported a reaction or health impact at least once during days 0–7 post-vaccination.